Remove q-and-a
article thumbnail

From winning SCOPE's Site Innovation Award to patient engagement and tech advancement, a Q&A with Medidata

Outsourcing Pharma

A Q&A session was held at SCOPE 2024 in Orlando, Outsourcing Pharma speaks with Kelly McGee, VP of decentralized clinical trials and patient registries, and Daniel Braga, VP of EHR and healthcare solutions.

64
article thumbnail

Optimizing Bispecific Antibodies in Multiple Myeloma for Efficacy, Safety

Drug Topics

A Q&A with Kirollos Hanna, PharmD, director of pharmacy at Minnesota Oncology, on the current and future landscape of bispecific antibodies in myeloma treatment.

207
207
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Diversity and Mentoring at BioPharmas: A C-Suite Q&A with Korn Ferry’s JT Saunders

PharmExec

In this latest Harvard Business School Healthcare Alumni Association Q&A, JT Saunders, Chief Diversity Officer at global consulting firm Korn Ferry, discusses diversity in pharma, as well as what mentors and mentees should be considering in the workplace.

98
article thumbnail

Q&A: Cell and gene therapy value assessments need a rework to allow access

Pharmaceutical Technology

Paolo Morgese, vice president of European public affairs at the Alliance for Regenerative Medicine, discusses the barriers affecting access to gene therapies.

85
article thumbnail

STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead

STAT

Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame with the same goal of turning the nascent CRISPR gene-editing technology into medicines. The former McKinsey partner joined CRISPR Therapeutics in 2015 as its chief business officer. In 2017, he was elevated to CEO.

122
122
article thumbnail

STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk

STAT

Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could alter people’s DNA. While the company celebrated, its founder, Joshua Boger, looked on like a proud parent. Boger, 72, founded Vertex in 1989 and served in various roles until 2017.

Labelling 128
article thumbnail

Independent Pharmacies Must Look Out For Deceptive PBM Practices

Drug Topics

A Q&A with Douglas Hoey, CEO of NCPA, on ways to change the pharmacy payment model and deceptive practices being employed by PBMs.